Venn Life Sciences Holdings PLC Innovenn Board Appointment
December 10 2014 - 1:01AM
RNS Non-Regulatory
TIDMVENN
Venn Life Sciences Holdings PLC
10 December 2014
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Innovenn Board Appointment
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing clinical trial management and
resourcing solutions to pharmaceutical, biotechnology and medical
device clients, announces the appointment of Gill Leates as
Non-Executive Director to the board of its subsidiary, Innovenn,
with immediate effect. The appointment was approved by the board of
Venn last week and comes on the back of the recent commencement of
production of its breakthrough skin research model, Labskin.
Gill brings extensive public market experience to Innovenn
having served as Investment Director on the main board of Majedie
Investments PLC from 1999 to 2008, and as a non-executive director
of Majedie Asset Management Limited during that period, where she
played a key role in setting up the UK pension fund management
business in 2002 and is now managing over GBP5bn. Prior to that she
successfully managed GBP1bn in the UK stock market for Courtaulds
Pension Fund. Whilst in her early career from 1981 to 1989 she
worked at Schroders on researching the US and UK, in corporate
finance, and then successfully managing the Schroders UK Smaller
Companies Exempt Fund. Since 2009 Gill has been a non-executive
Director of Hydrodec PLC, and is currently chairman of its Audit
Committee, and member of its Remuneration and Nomination
Committees. In March 2014 she was also appointed as non-executive
Chairman of Verdes Management PLC.
Commenting on the appointment, Venn CEO, Tony Richardson, said:
"We are very pleased to welcome Gill to the Board of Innovenn as a
Non-Executive Director. Gill's experience with public companies and
investment strategies fits exactly with our vision to develop
Innovenn as a leading skin science organisation."
Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Declan Service, Managing Director Tel: +353 877705506
Orla McGuinness Tel: +353 1 30826707
Zeus Capital (Nominated Adviser
and Broker)
Ross Andrews/Andrew Jones Tel: 0161 831 1512
Dominic Wilson Tel: 020 7533 7727
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About Innovenn
Innovenn (55.6% owned by Venn) is a market development
accelerator dedicated to rapidly commercialising proven scientific
breakthroughs in the form of products and technologies primarily in
Skin Science. These include Labskin the breakthrough research grade
human skin testing platform as well as the clinically proven
Blemish Control Technology for the professional skincare market.
For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing
clinical trial management solutions and resourcing solutions to
pharmaceutical, biotechnology and medical device organisations.
With dedicated operations in France, Germany, the Netherlands, the
UK and Ireland and Europe wide representation - Venn specialises in
rapid deployment and management of multisite projects. Venn
recently established an innovation division - Innovenn - focused
primarily on breakthrough development opportunities in Skin
Science.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFELFRLAIIS
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024